Corticosteroids Therapy and Pneumocystis Jirovecii Pneumonia (PCP)
Information source: George Washington University
ClinicalTrials.gov processed this data on August 23, 2015 Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Pneumocystis Carinii Pneumonia
Intervention: Antibiotics only (Drug); Antibiotics + Corticosteroids (Drug); Corticosteroids + antibiotics (Drug)
Phase: Phase 4
Status: Withdrawn
Sponsored by: George Washington University Official(s) and/or principal investigator(s): Afsoon Roberts, M.D., Principal Investigator, Affiliation: George Washington University Medical Faculty Associates
Summary
To explore the effects of corticosteroid therapy on pulmonary fibrosis and potentially
pneumothorax in patients with mild PCP (pO2 >70mmHg) combined with the standard of care
treatment of antibiotic therapy.
Clinical Details
Official title: Oral Corticosteroids Therapy and Interstitial Fibrosis in Patients With Pneumocystis Jirovecii Pneumonia (PCP) and pO2 of >70 at Presentation.
Study design: Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Primary outcome: Changes in pulmonary function testing and DLCO measurements in patients with PCP and pO2 > 70 mmHg.
Detailed description:
Although the development of highly active anti-retroviral therapy has substantially reduced
the incidence of Pneumocystis jirovecii pneumonia (PCP) among HIV-infected individuals, PCP
remains one of the most common presenting opportunistic infection among this population. The
use of adjunctive corticosteroids in the treatment of patients with moderate to severe PCP
has resulted in a significant improvement in the development of respiratory failure and
mortality.
Past studies have demonstrated no clinical benefit in patients with mild disease (pO2>75
torr on room air). This may have been due to the fact that few patients with mild disease
develop either respiratory failure or die during the course of the acute illness so that a
statistical difference could not be demonstrated.
However, considering parameters other than mortality, there is some evidence to suggest that
patients with high pO2 concentrations benefit from adjunctive corticosteroids. PCP is
associated with the development of pulmonary fibrosis and this can have significant
consequences. Pathological studies have shown the development of interstitial fibrosis late
in the course of acute illness. Studies have documented the presence of diffuse
interstitial pneumonitis five months after the onset of acute illness. Therefore, patients
with PCP infection, regardless of their pO2 level on presentation may benefit from
corticosteroid therapy.
The current standard of care therapy for patients with PCP does not involve the addition of
corticosteroids to standard antibiotics in those patients with pO2>70 mmHG. This study
propose to conduct a randomized, prospective, un-blinded clinical trial to explore the
effects of corticosteroid therapy on pulmonary fibrosis in patients with mild PCP who are
admitted to the George Washington University Hospital.
Eligibility
Minimum age: 18 Years.
Maximum age: N/A.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- HIV Infection,
- Hospital admission for suspected PCP,
- Confirmatory test for PCP (bronchoscopy with bronchoalveolar lavage), pO2>70 mmHg or
pO2<70 mmHg while breathing room air,
- 18 years or older
Exclusion Criteria:
- Contraindications to corticosteroid therapy,
- Unable and or unwilling to perform PFTS or to return for follow-up evaluations,
- Underlying lung disease such as emphysema, untreated active tuberculosis,
Uncontrolled diabetes (fasting glucose > 250 mg/dL,
- Uncontrolled hypertension (160/95 mmHg),
- Pregnancy
Locations and Contacts
George Washington University Medical Faculty Associates, Washington, District of Columbia 20037, United States
Additional Information
Related publications: Bozzette SA, Sattler FR, Chiu J, Wu AW, Gluckstein D, Kemper C, Bartok A, Niosi J, Abramson I, Coffman J, et al. A controlled trial of early adjunctive treatment with corticosteroids for Pneumocystis carinii pneumonia in the acquired immunodeficiency syndrome. California Collaborative Treatment Group. N Engl J Med. 1990 Nov 22;323(21):1451-7. Montaner JS, Lawson LM, Levitt N, Belzberg A, Schechter MT, Ruedy J. Corticosteroids prevent early deterioration in patients with moderately severe Pneumocystis carinii pneumonia and the acquired immunodeficiency syndrome (AIDS). Ann Intern Med. 1990 Jul 1;113(1):14-20. Nielsen TL, Eeftinck Schattenkerk JK, Jensen BN, Lundgren JD, Gerstoft J, van Steenwijk RP, Bentsen K, Frissen PH, Gaub J, Orholm M, et al. Adjunctive corticosteroid therapy for Pneumocystis carinii pneumonia in AIDS: a randomized European multicenter open label study. J Acquir Immune Defic Syndr. 1992;5(7):726-31. Gagnon S, Boota AM, Fischl MA, Baier H, Kirksey OW, La Voie L. Corticosteroids as adjunctive therapy for severe Pneumocystis carinii pneumonia in the acquired immunodeficiency syndrome. A double-blind, placebo-controlled trial. N Engl J Med. 1990 Nov 22;323(21):1444-50. Gallant JE, Chaisson RE, Moore RD. The effect of adjunctive corticosteroids for the treatment of Pneumocystis carinii pneumonia on mortality and subsequent complications. Chest. 1998 Nov;114(5):1258-63. Nowak J. Late pulmonary changes in the course of infection with Pneumocystis carinii. Acta Med Pol. 1966;7(1):23-41. Whitcomb ME, Schwarz MI, Charles MA, Larson PH. Interstitial fibrosis after Pneumocystis carinii pneumonia. Ann Intern Med. 1970 Nov;73(5):761-5. Sepkowitz KA, Telzak EE, Gold JW, Bernard EM, Blum S, Carrow M, Dickmeyer M, Armstrong D. Pneumothorax in AIDS. Ann Intern Med. 1991 Mar 15;114(6):455-9. Coker RJ, Moss F, Peters B, McCarty M, Nieman R, Claydon E, Mitchell D, Harris JR. Pneumothorax in patients with AIDS. Respir Med. 1993 Jan;87(1):43-7. Tumbarello M, Tacconelli E, Pirronti T, Cauda R, Ortona L. Pneumothorax in HIV-infected patients: role of Pneumocystis carinii pneumonia and pulmonary tuberculosis. Eur Respir J. 1997 Jun;10(6):1332-5.
Starting date: February 2008
Last updated: August 20, 2013
|